Sigyn Therapeutics, Inc. (OTCQB: SIGY), developer of CardioDialysis, a next-generation blood purification technology, disclosed today that researchers at Trinity College Dublin have reported the first clinical evidence of blood-brain barrier disruption and associated inflammation in living individuals suspected of having Chronic Traumatic Encephalopathy (CTE). The findings were published in the journal Science Translational Medicine and covered by Scientific American on March 21.
When the blood-brain barrier becomes compromised, inflammatory molecules and pathogenic toxins in the bloodstream can enter the brain, triggering neuroinflammation and abnormal accumulation of tau protein, a hallmark of CTE. The study observed that former athletes appeared to exist in a persistent state of chronic hyperinflammation. This adds to evidence that systemic inflammation drives neuroinflammation in disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.
CardioDialysis enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. Sigyn is pursuing a strategic transaction focused on using CardioDialysis to reduce systemic inflammation associated with traumatic brain injury (TBI). The Company’s lead clinical indication remains cardiovascular disease, the leading cause of death worldwide.
“It is becoming increasingly clear that CardioDialysis may play a meaningful role to slow the progression of neuroinflammatory disorders, particularly in high-risk individuals or during the early stages of disease,” stated Sigyn Therapeutics CEO Jim Joyce. “The dual reduction of inflammatory and pathogenic factors from the bloodstream could help stabilize the blood-brain barrier, which would limit the leakage of harmful molecules into the brain.”
CardioDialysis is the first therapy to integrate plasma separation and therapeutic adsorption within a single device. In cardiovascular disease, it aims to reduce inflammatory mediators and cholesterol-transporting lipoproteins. It is also being explored for sepsis, viral infections, and neurological disorders.
